Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.7 EUR | +0.79% |
|
-3.05% | -57.53% |
05-22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
05-21 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 147 | 175.2 | 130.3 | 84.95 | 44.36 | 20.18 | - | - |
Enterprise Value (EV) 1 | 139.6 | 178.9 | 140.3 | 96.95 | 44.36 | 37.29 | 33.71 | 20.18 |
P/E ratio | -19.6 x | -29 x | -22 x | -13.1 x | -6.49 x | 42.3 x | 9.53 x | 7.66 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 23.9 x | 21.6 x | 11.2 x | 7.53 x | 4.83 x | 1.11 x | 0.82 x | 0.67 x |
EV / Revenue | 22.7 x | 22 x | 12.1 x | 8.6 x | 4.83 x | 2.05 x | 1.37 x | 0.67 x |
EV / EBITDA | -23.7 x | -33.2 x | -40.1 x | -22.8 x | -9.97 x | 18.1 x | 6.68 x | 2.24 x |
EV / FCF | - | -16.5 x | - | -17.9 x | -9.53 x | 9.32 x | 3.81 x | 2.02 x |
FCF Yield | - | -6.07% | - | -5.6% | -10.5% | 10.7% | 26.3% | 49.6% |
Price to Book | - | 32.7 x | 681 x | -20.4 x | -4.39 x | -2.94 x | -3.55 x | - |
Nbr of stocks (in thousands) | 1,470 | 1,473 | 1,480 | 1,506 | 1,519 | 1,541 | - | - |
Reference price 2 | 100.0 | 119.0 | 88.00 | 56.40 | 29.20 | 13.10 | 13.10 | 13.10 |
Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.145 | 8.124 | 11.6 | 11.28 | 9.184 | 18.19 | 24.58 | 30.27 |
EBITDA 1 | -5.883 | -5.388 | -3.5 | -4.244 | -4.451 | 2.06 | 5.05 | 9.01 |
EBIT 1 | -6.21 | -5.816 | -4.1 | -4.914 | -5.129 | 1.05 | 4.035 | 8.41 |
Operating Margin | -101.07% | -71.59% | -35.34% | -43.58% | -55.85% | 5.77% | 16.41% | 27.78% |
Earnings before Tax (EBT) 1 | -7.212 | -6.007 | -5.7 | -6.391 | -6.791 | 0.51 | 2.27 | 3.24 |
Net income 1 | -7.216 | -6.01 | -5.9 | -6.398 | -6.795 | 0.47 | 2.09 | 2.59 |
Net margin | -117.44% | -73.98% | -50.86% | -56.74% | -73.99% | 2.58% | 8.5% | 8.56% |
EPS 2 | -5.100 | -4.100 | -4.000 | -4.300 | -4.500 | 0.3100 | 1.375 | 1.710 |
Free Cash Flow 1 | - | -10.85 | - | -5.43 | -4.657 | 4 | 8.85 | 10 |
FCF margin | - | -133.53% | - | -48.16% | -50.71% | 21.99% | 36% | 33.04% |
FCF Conversion (EBITDA) | - | - | - | - | - | 194.17% | 175.25% | 110.99% |
FCF Conversion (Net income) | - | - | - | - | - | 851.06% | 423.44% | 386.1% |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | 3.61 | 10 | 12 | - | 17.1 | 13.5 | - |
Net Cash position 1 | 7.38 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | -0.6695 x | -2.857 x | -2.829 x | - | 8.306 x | 2.679 x | - |
Free Cash Flow 1 | - | -10.8 | - | -5.43 | -4.66 | 4 | 8.85 | 10 |
ROE (net income / shareholders' equity) | - | -74.1% | -211% | - | - | 27.4% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 3.640 | 0.1300 | -2.760 | -6.650 | -4.460 | -3.690 | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 2.34 | 3.96 | - | 0.23 | 0.13 | 6.08 | 2 | 2.55 |
Capex / Sales | 38.1% | 48.79% | - | 2.02% | 1.4% | 33.42% | 8.14% | 8.42% |
Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.43% | 94.45B | |
-0.66% | 38.9B | |
-13.57% | 32.56B | |
+70.53% | 28.34B | |
-12.73% | 15.98B | |
-2.15% | 13.82B | |
-13.59% | 11.34B | |
+158.88% | 9.81B | |
-52.04% | 9.67B |
- Stock Market
- Equities
- MARI Stock
- 93Z Stock
- Financials Marinomed Biotech AG